ORPHA:443811
PGM3-CDG
Also known as: CID due to PGM3 deficiency · Combined immunodeficiency due to PGM3 deficiency · PGM3-related congenital disorder of glycosylation
Publications
1,341
Trials
0
Interventional, condition-specific
Researchers
1,527
Distinct authors in sample
Gene link
PGM3
Definitive
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare disorder of glycosylation caused by mutations in the PGM3 gene and characterized by to childhood onset of recurrent bacterial and viral infections, inflammatory skin diseases, atopic dermatitis and atopic diatheses, and marked serum IgE elevation. Early neurologic impairment is evident including , , , dysarthria, sensorineural hearing loss, myoclonus and .
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0014353
- MeSH:C565684
- OMIM:216920
- OMIM:615816
- UMLS:C4014371
Additional Mondo synonyms (10)
IMD23 · PGM3-EXACT congenital disorder of glycosylation · combined immunodeficiency due to PGM3 deficiency · combined inflammatory and immunologic defect · immunodeficiency 23 · immunodeficiency type 23 · immunodeficiency with hyper IgE and cognitive impairment · immunodeficiency-vasculitis-myoclonus syndrome · phosphoglucomutase 3 deficiency · phosphoglucomutase deficiency type 3
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Definitive — PGM3
- LiteraturePresent
1,341 matched papers (874 in last 10 years) Source
- Phenotype characterisedPresent
109 HPO annotations (e.g. Increased circulating IgM concentration; Hypotonia; Ataxia) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (PGM3).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
109
Associated phenotypes · MONDO:0014353
- Increased circulating IgM concentration
- Hypotonia
- Ataxia
- Generalized hypotonia
- Allergic rhinitis
Showing 5 of 109 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
1,341
1,341 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
1,341 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
874 in the last 10 years · low confidence
Phrase hits: 199 · MeSH hits: 0
Who's working on it?
1,527
Distinct author names in 199 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Jaeken J9 papers · 2023
Metabolic Center, Department of Pediatrics, University Hospitals Leuven, Herestraat 49, B-3000, Leuven, Belgium.
Papers in Europe PMC - 02Francisco R6 papers · 2024
UCIBIO, Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, Lisboa, Portugal.
Papers in Europe PMC - 03Videira PA6 papers · 2024
CDG & Allies-Professionals and Patient Associations International Network (CDG & Allies-PPAIN), Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, Caparica, 2825-149 Lisbon, Portugal.
Papers in Europe PMC - 04Dos Reis Ferreira V5 papers · 2024
CDG & Allies-Professionals and Patient Associations International Network (CDG & Allies-PPAIN), Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, Caparica, 2825-149 Lisbon, Portugal.
Papers in Europe PMC - 05Ferreira CR5 papers · 2024
Skeletal Genomics Unit, Metabolic Medicine Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, USA.
Papers in Europe PMC - 06Freeze HH5 papers · 2024
Laboratory of Immunology, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
Papers in Europe PMC - 07Milner JD5 papers · 2026
Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center Drive, Building 10/CRC, Room 5-3950, Bethesda, MD 20892, USA.
Papers in Europe PMC - 08Morava E5 papers · 2023
Metabolic Center, Department of Pediatrics, University Hospitals Leuven, Herestraat 49, B-3000, Leuven, Belgium. Morava-Kozicz.Eva@MAYO.edu.
Papers in Europe PMC - 09Pascoal C5 papers · 2024
CDG & Allies-Professionals and Patient Associations International Network (CDG & Allies-PPAIN), Departamento Ciências da Vida, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, Caparica, 2825-149 Lisbon, Portugal.
Papers in Europe PMC - 10Freeman AF4 papers · 2026
Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 10 Center Drive, Building 10/CRC, Room 12C103, Bethesda, MD 20892, USA. Electronic address: freemaal@mail.nih.gov.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name. 1 observational study did — shown below because natural-history and cohort work can be an important step toward a trial.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
low confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Observational and natural-history studies
1 observational study matches this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for PGM3-CDG — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("PGM3-CDG" OR "CID due to PGM3 deficiency" OR "Combined immunodeficiency due to PGM3 deficiency" OR "PGM3-related congenital disorder of glycosylation" OR "PGM3-related congenital disorder of the glycosylation" OR "IMD23" OR "PGM3-EXACT congenital disorder of glycosylation" OR "PGM3-EXACT congenital disorder of the glycosylation" OR "combined inflammatory and immunologic defect" OR "immunodeficiency 23" OR "immunodeficiency type 23" OR "immunodeficiency with hyper IgE and cognitive impairment" OR "immunodeficiency-vasculitis-myoclonus syndrome" OR "phosphoglucomutase 3 deficiency" OR "phosphoglucomutase deficiency type 3") OR (MESH:"Combined Inflammatory and Immunologic Defect") OR ("PGM3" OR "PGM3 syndrome" OR "PGM3-related")MeSH descriptor terms unioned into the query: Combined Inflammatory and Immunologic Defect
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"PGM3-CDG" OR "CID due to PGM3 deficiency" OR "Combined immunodeficiency due to PGM3 deficiency" OR "PGM3-related congenital disorder of glycosylation" OR "PGM3-related congenital disorder of the glycosylation" OR "IMD23" OR "PGM3-EXACT congenital disorder of glycosylation" OR "PGM3-EXACT congenital disorder of the glycosylation" OR "combined inflammatory and immunologic defect" OR "immunodeficiency 23" OR "immunodeficiency type 23" OR "immunodeficiency with hyper IgE and cognitive impairment" OR "immunodeficiency-vasculitis-myoclonus syndrome" OR "phosphoglucomutase 3 deficiency" OR "phosphoglucomutase deficiency type 3"
Study-type breakdown: 0 interventional · 1 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase, mesh; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is short or not clearly distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1341) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-27T16:27:20.170Z